EUVIMEDOpdag EUVIMED
Crossref

Shortening the biologics clinical timeline with a novel method for generating stable, high‐producing cell pools and clones

Chad A Hall, Rachel H Kravitz, Karl F Johnson, Nicholas A Sanek, Payel Maiti, Keith R Ziemba, Jia Liu, Dmitri O Andreev, Victoria L Chrostowski, Ian J Collins, Gregory T Bleck

Biotechnology and Bioengineering · 2025

DOI: 10.1002/bit.28323 ↗

At a glance

Journal article in Biotechnology and Bioengineering, 2025. Written by Chad A Hall and 10 co-authors. Institution: Catalent Pharma Solutions, Somerset, New Jersey, USA. Major MEDLINE topics: Biological Products. Cited 2 times so far (Crossref); 17 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Reducing drug development timelines is an industry‐wide goal to bring medicines to patients in need more quickly. This was exemplified in the coronavirus disease 2019 pandemic where reducing development timelines had a direct impact on the number of lives lost to the disease. The use of drug substances produced using cell pools, as opposed to clones, has the potential to shorten development timelines. Toward this goal, we have developed a novel technology, GPEx® Lightning, that allows for rapid, reproducible, targeted recombination of transgenes into more than 200 Dock sites in the Chinese hamster ovary cell line genome. This allows for rapid production of high‐expressing stable cell pools and clones that reach titers of 4–12 g/l in generic fed‐batch production. These pools and clones are highly stable in both titer and glycosylation, showing strong similarities in glycosylation profiles.

Subjects

MeSH terms (MEDLINE)

Biological ProductsCHO CellsCricetulusAnimalsCOVID-19HumansGlycosylationSARS-CoV-2CricetinaeBatch Cell Culture Techniques

Author keywords

CHO cellscell poolsexpressionsite‐specific recombination

Substances

Biological Products

Authors and institutions

  • Catalent Pharma Solutions, Somerset, New Jersey, USA.

Cite

APA

Hall, C. A., Kravitz, R. H., Johnson, K. F., Sanek, N. A., Maiti, P., Ziemba, K. R., Liu, J., Andreev, D. O., Chrostowski, V. L., Collins, I. J., & Bleck, G. T. (2025). Shortening the biologics clinical timeline with a novel method for generating stable, high‐producing cell pools and clones. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28323

Vancouver

Hall CA, Kravitz RH, Johnson KF, Sanek NA, Maiti P, Ziemba KR, et al. Shortening the biologics clinical timeline with a novel method for generating stable, high‐producing cell pools and clones. Biotechnology and Bioengineering. 2025. doi:10.1002/bit.28323

BibTeX
@article{Hall2025,
  author = {Hall, Chad A and Kravitz, Rachel H and Johnson, Karl F and Sanek, Nicholas A and Maiti, Payel and Ziemba, Keith R and Liu, Jia and Andreev, Dmitri O and Chrostowski, Victoria L and Collins, Ian J and Bleck, Gregory T},
  title = {Shortening the biologics clinical timeline with a novel method for generating stable, high‐producing cell pools and clones},
  journal = {Biotechnology and Bioengineering},
  year = {2025},
  doi = {10.1002/bit.28323}
}
Start for free →